Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference

Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference




Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference

TEMPLE CITY, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisse’s 31st Annual Healthcare Conference on Tuesday, November 8, 2022.

These representatives of the company will conduct a presentation beginning at approximately 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at the same location beginning approximately one hour following the completion of the event.

About Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.

Contacts

Investor Relations Contacts:
The Blueshirt Group

Melanie Solomon, melanie@blueshirtgroup.com